Jude Onyia's Insider Trades & SAST Disclosures
Jude Onyia's most recent trade in Neurocrine Biosciences, Inc. was a trade of 54,645 Stock Option done . Disclosure was reported to the exchange on Feb. 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jude Onyia.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 54,645 | 54,645 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 10,241 | 10,241 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,717 | 18,278 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,717 | 5,434 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,690 | 19,536 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,690 | 8,070 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 116.75 per share. | 12 Feb 2025 | 1,447 | 18,089 (0%) | 0% | 116.7 | 168,933 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 116.83 per share. | 12 Feb 2025 | 1,432 | 16,846 (0%) | 0% | 116.8 | 167,306 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 238 | 238 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 238 | 15,687 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 152.97 per share. | 31 Jan 2025 | 126 | 15,561 (0%) | 0% | 153.0 | 19,274 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 4,426 | 4,426 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Onyia Jude | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 4,426 | 17,780 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 126.29 per share. | 29 Nov 2024 | 2,331 | 15,449 (0%) | 0% | 126.3 | 294,373 | Common Stock |
| Voyager Therapeutics Inc | Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Neurocrine Biosciences, Inc. | Onyia Jude | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 54,069 | 54,069 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 10,760 | 10,760 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Onyia Jude | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 132.94 per share. | 13 Feb 2024 | 1,432 | 13,128 (0%) | 0% | 132.9 | 190,371 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 141.94 per share. | 31 Jan 2024 | 126 | 11,843 (0%) | 0% | 141.9 | 17,884 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 107.37 per share. | 21 Aug 2023 | 3,198 | 9,638 (0%) | 0% | 107.4 | 343,368 | Common Stock |
| Voyager Therapeutics Inc | Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 67,541 | 67,541 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,868 | 10,868 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 102.30 per share. | 07 Feb 2023 | 4,508 | 6,525 (0%) | 0% | 102.3 | 461,166 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 108.48 per share. | 31 Jan 2023 | 126 | 2,477 (0%) | 0% | 108.5 | 13,668 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 121.90 per share. | 29 Nov 2022 | 2,331 | 2,366 (0%) | 0% | 121.9 | 284,160 | Common Stock |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 6,464 | 6,464 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 950 | 950 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Nov 2021 | 120,169 | 120,169 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Nov 2021 | 17,702 | 17,702 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges